最新ニュース Septerna (NASDAQ:SEPN) 株価情報

SEPTERNA INC

Septerna

Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, GLP-1R, GIPR, and GCGR.

Septerna Inc

Vivid Seats (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEAT#NASDAQ">SEAT</a>) reported quarterly losses of $(0.05) per share which missed the analyst consensus estimate of $(0.01) by 400 percent. This is a 225 percent decrease over earnings of $0.04 per share from the same period last year. The company reported quarterly sales of $164.02 million which missed the analyst consensus estimate of $169.71 million by 3.35 percent. This is a 14.06 percent decrease over sales of $190.85 million the same period last year.

Earnings

Earnings Misses

News

SEAT

Vivid Seats Q1 EPS $(0.05) Misses $(0.01) Estimate, Sales $164.02M Miss $169.71M Estimate

Telsey Advisory Group analyst Dana Telsey maintains ThredUp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TDUP#NASDAQ">TDUP</a>) with a Outperform and raises the price target from $6 to $7.

Price Target

Analyst Ratings

TDUP

Telsey Advisory Group Maintains Outperform on ThredUp, Raises Price Target to $7

Brilliant Earth Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRLT#NASDAQ">BRLT</a>) reported quarterly earnings of $0.00 per share. This is a 96.67 percent decrease over earnings of $0.03 per share from the same period last year. The company reported quarterly sales of $93.88 million which missed the analyst consensus estimate of $94.35 million by 0.49 percent. This is a 3.55 percent decrease over sales of $97.34 million the same period last year.

BRLT

Brilliant Earth Group Q1 Adj. EPS $0.00 Down From $0.03 YoY, Sales $93.88M Miss $94.35M Estimate

Ferrari (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RACE#NYSE">RACE</a>) FY2025 expected to be more than $9.04 vs $8.97 Est. FY2025 Revenue expected to be more than $7.36B vs $7.20B Est

Guidance

RACE

Ferrari FY2025  expected to be more than $9.04 vs $8.97 Est; FY2025  Revenue expected to be more than $7.36B vs $7.20B Est

Brookfield Asset Mgmt (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAM#NYSE">BAM</a>) reported quarterly earnings of $0.36 per share which missed the analyst consensus estimate of $0.90 by 60 percent. This is a 33.33 percent increase over earnings of $0.27 per share from the same period last year. The company reported quarterly sales of $1.08 billion which missed the analyst consensus estimate of $1.41 billion by 23.28 percent. This is a 22.29 percent increase over sales of $884.00 million the same period last year.

Brookfield Asset Mgmt Q1 EPS $0.36 Misses $0.90 Estimate, Total Revenues $1.08B Miss $1.41B Estimate

Needham analyst David Saxon reiterates SI-BONE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIBN#NASDAQ">SIBN</a>) with a Buy and maintains $24 price target.

Reiteration

SIBN

Needham Reiterates Buy on SI-BONE, Maintains $24 Price Target

AG Mortgage Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MITT#NYSE">MITT</a>) reported quarterly earnings of $0.20 per share which beat the analyst consensus estimate of $0.17 by 17.65 percent. This is a 4.76 percent decrease over earnings of $0.21 per share from the same period last year. The company reported quarterly sales of $18.85 million which missed the analyst consensus estimate of $19.11 million by 1.38 percent. This is a 9.72 percent increase over sales of $17.18 million the same period last year.

Earnings Beats

MITT

CORRECTION: AG Mortgage Investment Q1 Adj. EPS $0.20 Beats $0.17 Estimate, Sales $18.85M Miss $19.11M Estimate

Ferrari (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RACE#NYSE">RACE</a>) reported quarterly earnings of $2.42 per share which beat the analyst consensus estimate of $2.32 by 4.31 percent. This is a 14.15 percent increase over earnings of $2.12 per share from the same period last year. The company reported quarterly sales of $1.88 billion which beat the analyst consensus estimate of $1.77 billion by 6.11 percent. This is a 9.41 percent increase over sales of $1.72 billion the same period last year.

Ferrari Q1 EPS $2.42 Beats $2.32 Estimate, Sales $1.88B Beat $1.77B Estimate

Jacobs Reaffirms FY25 Net Revenue Growth Of Mid-To-High Single Digits; Adj EPS Of $5.85-$6.20 Vs. $6.03 Est.

Telsey Advisory Group analyst Sarang Vora maintains Westrock Coffee (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WEST#NASDAQ">WEST</a>) with a Outperform and maintains $9 price target.

WEST

Telsey Advisory Group Maintains Outperform on Westrock Coffee, Maintains $9 Price Target

TopBuild Affirms FY2025 Sales Guidance of $5.05B-$5.35B vs $5.17B Est

SOPH

Sophia Genetics Affirms FY2025 Sales Guidance of $72.00M-$76.00M vs $73.39M Est

You would think that Warren Buffett and Charlie Munger, the legendary investing duo behind Berkshire Hathaway's runaway success, met in a boardroom or a business school.
In case you did, you were wrong! They were introduced to each other by a well-known doctor couple in Omaha, who probably had no idea of what they would go on to achieve together.
What Happened: In the late 1950s, Warren Buffett was a young money manager slowly but steadily building a reputation for himself.
One day, he received a phone call from Dorothy Davis, the wife of Dr. Eddie Davis, a prominent local couple. Keen to learn about his investing approach, they invited Buffett over to their home.
While Dorothy listened closely, Dr. Davis seemed distracted—until, abruptly, he declared that he would invest $100,000 with Buffett, who was managing only $500,000 in total at the time. Taken aback, Buffett asked why. Dr. Davis bluntly replied, "You remind me of Charlie Munger."
See Also: <a href="https://www.benzinga.com/news/management/25/05/45199066/berkshire-hathaway-stock-falls-following-buffetts-retirement-as-ceo">Berkshire Hathaway Stock Falls Following Buffett&#8217;s Retirement As CEO</a>
Why It Matters: That comment set off a domino effect. The Davises were family friends with the Mungers. When Munger came back to Omaha in 1959 after his father passed away, the Davises got the two men to meet over dinner.
Within minutes, both were laughing at each other's jokes, immediately bonding over shared "irreverence" and intellectual curiosity, as Munger described it in a <a href="https://www.youtube.com/watch?v=PBW06pdqz7Y">joint interview</a> in 2022.
Munger joked that their wives thought, "My God, another one," but to Buffett and him, it was the beginning of a lifelong partnership that ended with <a href="https://www.benzinga.com/news/23/11/35989969/charlie-munger-buffetts-trusted-partner-dies-at-99">Munger's death in 2023</a>.
On Saturday, Buffett announced his decision to <a href="https://www.benzinga.com/25/05/45184410/warren-buffett-to-step-down-as-berkshire-hathaway-ceo-by-end-of-year-asks-board-to-confirm-greg-abel-as-successor">step down as Berkshire Hathaway CEO</a> at the end of this year, marking the end of an illustrious journey where Munger and his friendship played an indelible part.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/management/25/05/45188605/youve-got-to-check-emotions-at-the-door-warren-buffett-offers-timeless-investing-wisdom-amid-market-turmoil">&#8216;You&#8217;ve Got To Check Emotions At The Door:&#8217; Warren Buffett Offers Timeless Investing Wisdom Amid Market Turmoil</a></li>
</ul>
Photo courtesy: Kent Sievers/Shutterstock

Success Stories

General

Warren Buffett Met Charlie Munger In The 1950s Thanks To The Davises After A $100,000 Investment, Felt Instant Chemistry Over Dinner

TopBuild (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLD#NYSE">BLD</a>) reported quarterly earnings of $4.63 per share which beat the analyst consensus estimate of $4.42 by 4.75 percent. This is a 3.74 percent decrease over earnings of $4.81 per share from the same period last year. The company reported quarterly sales of $1.23 billion which met the analyst consensus estimate. This is a 3.57 percent decrease over sales of $1.28 billion the same period last year.

TopBuild Q1 Adj. EPS $4.63 Beats $4.42 Estimate, Sales $1.23B Inline

Brazil Potash Corp. ("Brazil Potash" or the "Company") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GRO#NYSE">GRO</a>), a mineral development company with a critical mineral potash mining project, today announced that it has entered into a definitive agreement establishing an equity line of credit ("ELOC") with Alumni Capital LP ("Alumni"), an institutional investor. Brazil Potash anticipates that this agreement will provide the company with a flexible source of funding, enabling the Company to progress its flagship Autazes Potash Project.
As Brazil Potash works towards key milestones, it anticipates the ELOC will enable judicious planning for the timing and amount of any equity sales, which will be critical as it advances site preparation and construction activities for the fully-permitted Autazes Project.
Under the terms of the agreement, Brazil Potash has the right to sell, and Alumni has the obligation to purchase, up to $75 million worth of common shares over a 24-month period at prices that are based on the market price at the time of each sale to Alumni, subject to the satisfaction of certain customary conditions. Brazil Potash, at its sole discretion, controls the timing and amount of all sales of common shares associated with the ELOC, subject to the limitations contained in the SPA.
 &nbsp;

Brazil Potash Agrees On Establishing Equity Line Of Credit With Alumni Capital To Progress Flagship Autazes Potash Project

HC Wainwright &amp; Co. analyst Heiko Ihle maintains Solaris Resources (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SLSR#AMEX">SLSR</a>) with a Buy and raises the price target from $10 to $11.

SLSR

HC Wainwright & Co. Maintains Buy on Solaris Resources, Raises Price Target to $11

Sophia Genetics Q1 EPS $(0.26), Inline, Sales $17.78M Beat $16.93M Estimate

Jacobs Solutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/J#NYSE">J</a>) reported quarterly earnings of $1.43 per share which beat the analyst consensus estimate of $1.39 by 2.88 percent. This is a 25.13 percent decrease over earnings of $1.91 per share from the same period last year. The company reported quarterly sales of $2.91 billion which beat the analyst consensus estimate of $2.18 billion by 33.48 percent. This is a 31.83 percent decrease over sales of $4.27 billion the same period last year.

Jacobs Solutions Q2 Adj. EPS $1.43 Beats $1.39 Estimate, Sales $2.91B Beat $2.18B Estimate

Telsey Advisory Group analyst Dana Telsey maintains a.k.a. Brands Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AKA#NYSE">AKA</a>) with a Market Perform and lowers the price target from $18 to $9.

Telsey Advisory Group Maintains Market Perform on a.k.a. Brands Holding, Lowers Price Target to $9

Marathon Petroleum (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPC#NYSE">MPC</a>) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.53) by 54.72 percent. This is a 108.63 percent decrease over earnings of $2.78 per share from the same period last year. The company reported quarterly sales of $31.85 billion which beat the analyst consensus estimate of $29.58 billion by 7.66 percent. This is a 4.10 percent decrease over sales of $33.21 billion the same period last year.

Marathon Petroleum Q1 EPS $(0.24) Beats $(0.53) Estimate, Sales $31.85B Beat $29.58B Estimate

Press Releases

Septerna Announces Discontinuation of SEP-786 Phase 1 Clinical Trial and Plans to Advance Next-Generation Oral Small Molecule PTH1R Agonist

Legal

Septerna, Inc. Investors: Company Investigated by the Portnoy Law Firm

Kirby McInerney LLP Announces Investigation Against Septerna, Inc. (SEPN) on Behalf of Investors

SEPTERNA ALERT: Bragar Eagel & Squire, P.C. is Investigating Septerna, Inc. on Behalf of Septerna Stockholders and Encourages Investors to Contact the Firm

Comments

Septerna

ニュース

最新ニュース Septerna (NASDAQ:SEPN) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル